Evidencia de la carbetocina en la hemorragia obstétrica
Artículo revisado por pares
Enviado: 13-01-2023
Revisado: 10-02-2023
Aceptado: 25-03-2023
Publicado: 26-03-2023
Editor: Dr. William Castillo González, https://orcid.org/0000-0003-3007-920X
DOI:
https://doi.org/10.56294/saludcyt2023341Palabras clave:
Prevención de la HPP, Hemorragia posparto, Carbetocina, OxitocinaResumen
Introducción: un procedimiento habitual es administrar agentes de uterotónicos de forma regular para la profilaxis de hemorragia postparto y poscesárea. El fármaco uterotónico típico aconsejado para este uso es la oxitocina, sin embargo, existe literatura que indica mejores efectos beneficios con la carbetocina debido a que presenta una actividad uterotónica sostenida y prolongada, además es segura y bien tolerada.
Objetivo: esbozar los datos de carbetocina que se han encontrado hasta ahora en relación con la hemorragia obstétrica.
Métodos: Para esta revisión bibliográfica se localizaron palabras clave relacionadas con el tema de la carbetocina en la hemorragia obstétrica mediante descriptores en ciencias de la salud, y posteriormente se buscaron en bases de datos y buscadores como Google Scholar, Pubmed, Lilacs, SciELO, Cochrane y Pubmed. De un total de 100 bibliografías fueron considerados 32 artículos.
Resultados: la carbetocina es un fármaco termoestable con una semivida aproximadamente 4-10 veces superior a la oxitocina, con la actividad uterotónica sostenida solo con la administración de una dosis única (100 μg) por vía intravenosa o intramuscular.
Conclusiones: la carbetocina es un fármaco seguro para la prescripción en pacientes que presenten patologías específicas, ya que mantiene un efecto uterotónico prologando, útil en las hemorragias poscerárea. Su uso aún no está totalmente promulgado debido al alto costo que representa en la actualidad.
Métricas
Citas
Voon, Hian Yan, et al. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries. Taiwanese Journal of Obstetrics and Gynecology. 2018; 57(3):332-339. https://doi.org/10.1016/j.tjog.2018.04.002
Elbohoty, Ahmed EH, et al. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. International Journal of Gynecology & Obstetrics. 2016; 134(3):324-328. https://doi.org/10.1016/j.ijgo.2016.01.025
Widmer, Mariana, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials. 2016; 17(1):1-9. https://doi.org/10.1186/s13063-016-1271-y
Briones, Jamaica Roanne, et al. Economic evaluation of carbetocin as prophylaxis for postpartum hemorrhage in the Philippines. BMC health services research. 2020; 20(1):1-12. https://doi.org/10.1186/s12913-020-05834-x
Chen, Chih-Yao, et al. Carbetocin in prevention of postpartum hemorrhage: experience in a tertiary medical center of Taiwan. Taiwanese Journal of Obstetrics and Gynecology. 2016; 55(6):804-809. https://doi.org/10.1016/j.tjog.2016.07.009
Gil-Rojas, Yaneth, et al. Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia. Revista Brasileira de Ginecologia e Obstetrícia. 2018; 40:242-250. https://doi.rog/10.1055/s-0038-1655747
MSP. Score Mama y Claves Obstétricas. En G. d. Clínica, Clave Roja (págs. 20- 30). Quito, Ecuador 2017.
MSP. Instituto Nacional de Estadísticas y Censos. https://www.salud.gob.ec/wpcontent/uploads/2018/05/CIERRE-PROCESO-MM-2018.pdf
Vogel, Joshua P., et al. WHO recommendations on uterotonics for postpartum haemorrhage prevention: ¿what works, and which one? BMJ global health. 2019; 4(2):e001466. http://dx.doi.org/10.1136/bmjgh-2019-001466
Tran, Nguyen Toan, et al. Implementing Heat-Stable Carbetocin for Postpartum Haemorrhage Prevention in Low-Resource Settings: A Rapid Scoping Review. International Journal of Environmental Research and Public Health. 2022;19(7):3765. https://doi.org/10.3390/ijerph19073765
Matthijsse, Suzette, et al. Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom. Journal of Medical Economics. 2022; 25(1):129-137. https://doi.org/10.1080/13696998.2022.2027669
Theunissen, Fiona J.; Chinery, Lester; Pujar, Yeshita V. Current research on carbetocin and implications for prevention of postpartum haemorrhage. Reproductive Health. 2018; 15(1):55-59. https://doi.org/10.1186/s12978-018-0529-0
You, Joyce HS; Leung, Tak-yeung. Cost-effectiveness analysis of carbetocin for prevention of postpartum hemorrhage in a low-burden high-resource city of China. Plos One. 2022; 17(12):e0279130. https://doi.org/10.1371/journal.pone.0279130
Van Der Nelson, Helen, et al. Intramuscular oxytocin versus oxytocin/ergometrine versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: study protocol for a randomised controlled trial (the IMox study). Trials. 2019;20:1-10. https://doi.org/10.1186/s13063-018-3109-2
Malm M, Madsen I, & Kjellström J. Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries. Journal of Peptide Science. 2018;24(6):e3082. https://doi.org/10.1002/psc.3082
AI, Wen, et al. Side‐effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta‐analysis of randomized controlled trials. Pharmacology Research & Perspectives. 2021; 9(2):e00745. https://doi.org/10.1002/prp2.745
Mannaerts, D., et al. Adverse effects of carbetocin versus oxytocin in the prevention of postpartum haemorrhage after caesarean section: a randomized controlled trial. Journal of pregnancy. 2018;(2018). https://doi.org/10.1155/2018/1374150
Van Der Nelson, Helen A., et al. Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: an economic impact analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017;210:286-291. https://doi.org/10.1016/j.ejogrb.2017.01.004
Brzozowska, Maria, et al. Comparison of carbetocin and oxytocin effectiveness for prevention of postpartum hemorrhage after caesarean delivery. Ginekologia polska. 2015;86(2). https://doi.org/10.17772/gp/1996
Martínez Díaz, Paula, et al. Análisis de la efectividad de la carbetocina comparada con la oxitocina en la prevención de la hemorragia postparto tras cesárea en embarazos gemelares. 2020. https://repositorio.unican.es/xmlui/bitstream/handle/10902/19435/MARTINEZ%20DIAZ%2c%20PAULA.pdf?sequence=1&isAllowed=y
Suárez González, Juan Antonio, et al. Uso de carbetocina frente al uso de oxitocina en pacientes intervenidas por cesárea con alto riesgo de atonía uterina. Revista Cubana de Obstetricia y Ginecología. 2017;43(2):1-10.
Vásquez Ordóñez, Ligia Irene. Efectividad de la carbetocina en la prevención de la hemorragia posparto. 2015. Tesis Doctoral. Universidad de San Carlos de Guatemala. http://www.repositorio.usac.edu.gt/8899/1/Ligia%20Irene%20V%C3%A1squez%20Ord%C3%B3%C3%B1ez.pdf
Ibrahim, Khalid Abd Aziz Mohamad; SAAD, Ahmed Samy. Prevention of postpartum haemorrhage in patients with severe preeclampsia using carbetocin versus misoprostol. Apollo medicine. 2017; 14(2):117-122. https://doi.org/10.1016/j.apme.2017.02.008
Abd El Aziz, Mohamed A., et al. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. Systematic Reviews. 2018;7:1-8. https://doi.org/10.1186/s13643-018-0832-4
Delorme, Pierre, et al. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage in cesarean deliveries: a retrospective study of two consecutive periods. American Journal of Perinatology Reports. 2020;10(03):e241-e246. https://doi.org/10.1055/s-0040-1715163
Barrett, Jon; KO, Samuel; Jeffery, William. Cost implications of using carbetocin injection to prevent postpartum hemorrhage in a Canadian urban Hospital. Journal of Obstetrics and Gynaecology Canada. 2022;44(3):272-278. https://doi.org/10.1016/j.jogc.2021.09.022
Tse, K. Y.; Florrie, N. Y.; Leung, K. Y. Comparison of carbetocin and oxytocin infusions in reducing the requirement for additional uterotonics or procedures in women at increased risk of postpartum haemorrhage after Caesarean section. Hong Kong Medical Journal. 2020; 26(5):382.
Robledo, Francisco Javier Posadas. Uso de la carbetocina para prevenir la hemorragia obstétrica. Ginecologia y Obstetricia de Mexico. 2011; 79(07):419-427.
Abundio Samano, Verónica. Efectividad de carbetocina en prevención de hemorragia obstétrica asociada a hipotonia uterina. 2012. https://cdigital.uv.mx/bitstream/handle/123456789/47037/AbundioSamanoVeronica.pdf?sequence=1
Abdelhamid, Ahmad N., et al. Comparison of the effect of carbetocin versus oxytocin during cesarean section in women with high risk of postpartum hemorrhage. Menoufia Medical Journal. 2019;32(4):1333.
Acevedo Amarillas, Humberto. Comparación de la eficacia de carbetocina vs oxitocina para prevenir hemorragia obstétrica. 2012. https://repositorioinstitucional.uabc.mx/bitstream/20.500.12930/4065/1/MED013734.pdf
Gallos, Ioannis, et al. Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis. Health Technology Assessment (Winchester, England). 2019(23)9:1. https://doi.org/10.3310%2Fhta23090
Seow, Kok-Min, et al. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in infertile women with twin pregnancy undergoing elective cesarean delivery. Taiwanese Journal of Obstetrics and Gynecology. 2017;56(3):273-275. https://doi.org/10.1016/j.tjog.2017.04.001
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Edison Andrés Tixe Lluglla, María Carolina Chalan Analuisa, Inés Paulina Panimboza Guamán, Jhon Michael Sanaguano Castillo, Pablo Rodrigo Escobar Castillo, Fernanda Gabriela Dután Ortiz, Paola Elizabeth Serpa Román, Michelle Estefanía Quispe Punina
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Este artículo se distribuye bajo la licencia Creative Commons Attribution 4.0 License. A menos que se indique lo contrario, el material publicado asociado se distribuye bajo la misma licencia.
